Relay Therapeutics Hits New 52-Week High of $18.92, Up 136.79%

Relay Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 18.92 on June 25, 2026. This achievement underscores the company's notable performance within the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 1,716 million. Over the past year, Relay Therapeutics has demonstrated impressive growth, with a performance increase of 136.79%, significantly outpacing the S&P 500's 20.77% gain during the same period. Despite its loss-making status, indicated by a negative price-to-earnings ratio, the company continues to attract attention due to its innovative approaches in the industry. Financial metrics reveal a price-to-book ratio of 3.03, while the company maintains a debt-to-equity ratio of -0.97, suggesting a unique financial structure. However, it is important to note that Relay Therapeutics does not offer a dividend yield, reflecting its focus on reinvesting in growth opportunities. The stock's previous 52-week low was recorded at USD 3.03, highlighting the substantial upward movement in its valuation.